ArticleFrontiers in oncology2026
Lattice SFRT in a geriatric patient with an initially inoperable leg bulky sarcoma: case report and literature review.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Management of inoperable bulky soft tissue sarcomas mostly in geriatric patients presents a significant clinical challenge due to high and hypoxia-induced radioresistance, proximity to dose-limiting Organs at Risk (OARs), and the need to minimize systemic toxicity. Spatially Fractionated Radiation Therapy (SFRT), specifically 3D Lattice Radiation Therapy (LRT), offers a novel approach to safely escalate dose within the tumor volume. Case presentation: 85-year-old female presenting a massive (20.7 x 9.8 cm), inoperable high-grade pleomorphic liposarcoma (FNCLCC Grade 3) of the right thigh. A hybrid fractionation approach was employed, consisting of conventional Volumetric Modulated Arc Therapy (VMAT) (40 Gy in 20 fractions) to the Clinical Target Volume (CTV), concurrently integrated with a weekly Lattice boost of 10 Gy, for 3 times, targeting 4 specific series of spatial vertices (Sup1, Sup2, Inf1, Inf2) using a strip-field technique. Remarkably, physical examination during the fourth week revealed a dramatic reduction in tumor consistency and pain relief. Conclusion: The tailored hybrid treatment was exceptionally well tolerated with no severe acute skin toxicity. The 4-month follow-up MRI showed stable external dimensions with internal coagulative necrosis, allowing adjuvant surgery. This case highlights the feasibility, safety, and tolerability of a response-adapted weekly hybrid LRT approach for bulky extremity sarcomas especially in frail populations. We also provide a brief review of the emerging literature on SFRT/LRT in bulky sarcomas and frail patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.